Develops drugs for hematology and oncology diseases.
Dec 2025Revenue $20.7M/yrExpenses $65.7M/yr
No trendCash runway ≈ 3 months from Dec 2025
Figures by year
When will CASI Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $20.7M and expenses $65.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $20.7M | $65.7M | −$45.0M |
| Dec 2024 | $28.5M | $68.2M | −$39.6M |
| Dec 2023 | $33.9M | $59.0M | −$25.1M |
| Dec 2022 | $43.1M | $77.1M | −$34.0M |
| Dec 2021 | $30.2M | $71.7M | −$41.5M |
| Dec 2020 | $15.1M | $67.9M | −$52.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.